Podsumowanie zaleceń postępowania we wrodzonym obrzęku naczynioruchowym z niedoboru C1 inhibitora

• Authors: Katarzyna Piotrowicz-Wójcik , Marcin Stobiecki , Krystyna Obtułowicz , Grzegorz Porębski

Title variants

EN

Summary of recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency

• Languages of publication: PL EN

Abstracts

PL

W pracy podsumowano, w świetle zaktualizowanych danych, zalecenia Sekcji Wrodzonego Obrzęku Naczynioruchowego Polskiego Towarzystwa Alergologicznego dotyczące postępowania w tym schorzeniu. Omówiono jego klasyfikację, patomechanizm, obraz kliniczny i rozpoznawanie. Przedstawiono zasady leczenia i zapobiegania napadom obrzęku oraz monitorowania choroby. Wymieniono cechy charakterystyczne odnoszące się do przebiegu i postępowania w okresie ciąży i w pediatrycznej grupie chorych.

EN

The paper summarizes the recommendations of the Hereditary Angioedema Section of the Polish Society of Allergology regarding the management of this disease in a view on up-to-date data. Its classification, pathomechanism, clinical picture and diagnosis were discussed. The principles of treatment and prevention of edema attacks and disease monitoring were presented. Characteristic features related to the course and management during pregnancy and in the pediatric group of patients were mentioned.

Keywords

EN

HAE; inhibitor C1; wrodzony obrzęk naczynioruchowy; zalecenia

Discipline

• MEDICINE: MEDICINE

• Publisher: Oficyna Wydawnicza Mediton
• Journal: Alergia Astma Immunologia - przegląd kliniczny
• Year: 2018
• Volume: 23
• Issue: 4
• Pages: 199-204

Contributors

author

Katarzyna Piotrowicz-Wójcik

• Zakład Alergologii Klinicznej i Środowiskowej, Uniwersytet Jagielloński Collegium Medicum w Krakowie

author

Marcin Stobiecki

• Zakład Alergologii Klinicznej i Środowiskowej, Uniwersytet Jagielloński Collegium Medicum w Krakowie

author

Krystyna Obtułowicz

• Zakład Alergologii Klinicznej i Środowiskowej, Uniwersytet Jagielloński Collegium Medicum w Krakowie

author

Grzegorz Porębski

• Zakład Alergologii Klinicznej i Środowiskowej, Uniwersytet Jagielloński Collegium Medicum w Krakowie

References

• 1. Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol 2009; 161: 1153-8.
• 2. Zanichelli A, Arcoleo F, Barca MP, et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy. Orphanet J Rare Dis 2015; 10: 11.
• 3. Germenis AE, Speletas M. Genetics of hereditary angioedema revisited. Clin Rev Allergy Immunol 2016; 51: 170-82.
• 4. López-Lera A, Garrido S, Roche O, et al. SERPING1 mutations in 59 families with hereditary angioedema. Mol Immunol 2011; 49: 18- 27.
• 5. Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000; 106: 1147-54.
• 6. Donaldson VH, Rosen FS. Action of complement in hereditary angioneurotic edema: the role of C1-esterase. J Clin Invest 1964; 43: 2204-13.
• 7. Kaplan AP, Joseph K. Complement, kinins, and hereditary angioedema: mechanisms of plasma instability when C1 inhibitor is absent. Clin Rev Allergy Immunol 2016; 51: 207-15.
• 8. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet. 1998; 351: 1693-7.
• 9. Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 2002; 109: 195-209.
• 10. Donaldson VH. Kinin formation in hereditary angioneurotic edema (HANE) plasma. Int Arch Allergy Appl Immunol 1973; 45: 206-9.
• 11. Whalley ET, Amure YO, Lye RH. Analysis of the mechanism of action of bradykinin on human basilar artery in vitro. Naunyn Schmiedebergs Arch Pharmacol 1987; 335: 433-7.
• 12. Whalley ET, Nwator IA, Stewart JM, et al. Analysis of the receptors mediating vascular actions of bradykinin. Naunyn Schmiedebergs Arch Pharmacol 1987; 336: 430-3.
• 13. Jacques L, Couture R, Drapeau G, et al. Capillary permeability induced by intravenous neurokinins. Receptor characterization and mechanism of action. Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 170-9.
• 14. Fields T, Ghebrehiwet B, Kaplan AP. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin. J Allergy Clin Immunol 1983; 72: 54-60.
• 15. Björkqvist J, de Maat S, Lewandrowski U, et al. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest 2015; 125: 3132-46.
• 16. de Maat S, Björkqvist J, Suffritti C, et al. Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. J Allergy Clin Immunol 2016; 138: 1414-23.
• 17. Porębski G, Gocki J, Juchacz A i wsp. Postępowanie we wrodzonym obrzęku naczynioruchowym z niedoboru inhibitora C1– stanowisko Sekcji HAE Polskiego Towarzystwa Alergologicznego. Część I: klasyfikacja, patofizjologia, objawy kliniczne i rozpoznanie. Alergologia Polska – Polish Journal of Allergology 2018; 5: 98-108.
• 18. Lang DM, Aberer W, Bernstein JA, et al. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol 2012; 109: 395-402.
• 19. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/ EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. Allergy 2018; 73: 1575-96.
• 20. Pedrosa M, Phillips-Angles E, Lóopez-Lera A, et al. Complement study versus CINH gene testing for the diagnosis of type I hereditary angioedema in children. J Clin Immunol 2016; 36: 16-18.
• 21. Ebo DG, Van Gasse AL, Sabato V, et al. Hereditary angioedema in 2 sisters due to paternal gonadal mosaicism. J Allergy Clin Immunol Pract 2017; 6: 277-9.
• 22. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69: 602-16.
• 23. Craig T, Aygören-Pürsün E, Bork K, et al. WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J 2012; 5: 182-99.
• 24. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71: 206-15.
• 25. Zotter Z, Csuka D, Szabó E, et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis 2014; 9: 44.
• 26. Reshef A, Prematta MJ, Craig TJ. Signs and symptoms preceding acute attacks of hereditary angioedema: results of three recent surveys. Allergy Asthma Proc 2013; 34: 261-6.
• 27. Magerl M, Doumoulakis G, Kalkounou I, et al. Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema. Clin Exp Dermatol 2014; 39: 298-303.
• 28. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130: 692-7.
• 29. Charakterystyka Produktu leczniczego Berinert http://leki.urpl.gov. pl/ (dostęp 12.10.2018).
• 30. Charakterystyka Produktu leczniczego Ruconest http://leki.urpl.gov. pl/ (dostęp 12.10.2018).
• 31. Charakterystyka Produktu leczniczego Firazyr http://leki.urpl.gov.pl/ (dostęp 12.10.2018).
• 32. https://indeks.mp.pl/leki/ (dostęp 12.10.2018)
• 33. Porębski G, Gocki J, Juchacz A i wsp. Postępowanie we wrodzonym obrzęku naczynioruchowym z niedoboru inhibitora C1 - stanowisko Sekcji HAE Polskiego Towarzystwa Alergologicznego. Część II: leczenie i zapobieganie napadom, monitorowanie choroby i postępowanie w sytuacjach szczególnych. Alergologia Polska – Polish Journal of Allergology 2018; 5: 109-20.
• 34. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-8.
• 35. Porebski G, Bilo B, Obtułowicz K i wsp. Rekombinowany C1-inhibitor jest skuteczny w leczeniu ostrych napadów wrodzonego obrzę- ku naczynioruchowego - opis przypadków. Przegl Lek 2005; 62: 317-20.
• 36. Zanichelli A, Vacchini R, Badini M, et al. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2011; 66: 192-6.
• 37. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-57.
• 38. Caballero T, Baeza ML, Cabañas R, et al. Consensus Statement on the Diagnosis, Management, and Treatment of Angioedema Mediated by Bradykinin. Part II. Treatment, Follow-up, and Special Situations. J Investig Allergol Clin Immunol 2011; 21: 422-41.
• 39. Frank MM. Update on preventive therapy (prophylaxis) for hereditary angioedema. Immunol Allergy Clin North Am 2013; 33: 495- 503.
• 40. Porebski G, Reshef A, Moldovan D. The prophylaxis of hereditary angioedema attacks with recombinant human C1 inhibitor: who will take advantage of the individualized treatment approach? Allergy 2013; 68: 1207-9.
• 41. Bernstein JA, Manning ME, Li H, et al. Escalating doses of C1 esterase inhibitor (Cinryze) for prophylaxis in patients with hereditary angioedema. J Allergy Clin Immunol Pract 2014; 2: 77-84.
• 42. Longhurst H, Cicardi M, Craig T, et al. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. N Engl J Med 2017; 376: 1131-40.
• 43. Porebski G, Obtułowicz K. Atenuowane androgeny w leczeniu wrodzonego obrzęku naczynioruchowego. Alergol Immunol 2015; 12: 21-5.
• 44. Maurer M, Magerl M. Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives. JDDG 2011; 9: 99-107.
• 45. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008; 100: 153-61.
• 46. Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol 2002; 36: 707-9.
• 47. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972; 287: 452-4.
• 48. Farkas H, Zotter Z, Csuka D, et al. Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor ‒ a long-term survey. Allergy 2012; 67: 1586-93.
• 49. Frank MM. Hereditary angioedema: short-term prophylaxis for surgery. Allergy Asthma Proc 2012; 33: 303-4.
• 50. Aygören-Pürsün E, Martinez Saguer I, Kreuz W, et al. Risk of angioedema following invasive or surgical procedures in HAE type I and II- the natural history. Allergy 2013; 68: 1034-9.
• 51. Magerl M, Frank M, Lumry W, et al. Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry. Ann Allergy Asthma Immunol 2017; 118: 110-12.
• 52. Banerji A, Riedl M. Managing the female patient with hereditary angioedema. Womens Health (Lond) 2016; 12: 351-61.
• 53. Bouillet L, Longhurst H, Boccon-Gibod I, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol 2008; 199: 1-4.
• 54. Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012; 129: 308-20.
• 55. Obtułowicz K, Porębski G, Bilo B i wsp. Przebieg wrodzonego obrzę- ku naczynioruchowego z niedoboru C1 inhibitora u kobiet podczas ciąży i porodu. Alergia Immunologia Astma 2008; 13: 91-9.
• 56. Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy 2017; 72: 300-13.
• 57. Obtułowicz K. Current Status of Diagnosis, Registry and Management of Hereditary Angioedema (HAE) in Poland. Alergol Immunol 2016; 13: 19-21.

• Document Type: article